Skip to main content

Table 5 Steady-state cerebrospinal fluid amyloid-β 1–40 reduction from baseline at 3 to 6 hours postdose, based on population pharmacokinetic/pharmacodynamic modeling from Study ALZ1005

From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

JNJ-54861911 dose (mg) Steady-state CSF Aβ1–40 percent reductions from baseline
5th percentile Median 95th percentile
5 27% 52% 72%
10 45% 67% 81%
20 63% 80% 90%
25 69% 84% 92%
30 72% 85% 93%
50 80% 91% 96%
  1. Amyloid-beta, CSF Cerebrospinal fluid